Michael Marcus, MD Director Pediatric Allergy & Pulmonary -Maimonides Medical Center . Fellowship:Childrens Hospital of Philadelphia Castle Connolly Top Doctor
Read the full transcript »
The Restrictions on FluMist Nasal Spray Flu Vaccine Use Male: Is there a group of individuals that cannot get the live vaccine? Michael Marcus: There is a small subgroup which comes out to maybe 20% of the population where the vaccine is not yet approved. It is not approved for children less than two years of age because we don’t have sufficient study showing its safety under two years of age. It’s also not approved for children who have severe asthma or who had at least three episodes of active wheezing absorb by a physician within a twelve-month period because again we do not have safety data yet in this subgroup of patients. And so until more studies are done in this subgroup of patients, we do not feel comfortable yet giving vaccine. Patients who had bad reactions, allergic reactions to the components of the vaccine should also not get the vaccine, and we don’t have a lot of information in patients of other severe chronic diseases or primary or required immune deficiency syndromes. And so we avoided in that group even though we have never seen any harmful reaction in that group when patients have been given the vaccine in those specific subgroups. Male: What about adults over 50 that’s not recommended with this particular plan? Michael Marcus: The vaccine also has not been tested in adult over the age of 49. So 50-year-old and older should not use the vaccine yet since we don’t have any data to show safety and efficacy.